Opicapone
Who holds supplier records for Opicapone? 4 organisations hold a current record for Opicapone: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (2) and China (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Opicapone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/opicapone
Reading the evidence
- 4 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
2 of the 3 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 3 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Opicapone expires 12 Dec 2032. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (4)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Opicapone. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIAL PORTELA AND CA SACompany GMP cert on recordActive DMF 34838, 32198 · latest filing Jul 2020
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 41566 · latest filing Mar 2025
- Jiangxi Synergy Pharmaceutical Co., LtdChinaActive DMF 42988 · latest filing Nov 2025
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 38110 · latest filing Mar 2023
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Opicapone). The latest listed patent expires 12 Dec 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Opicapone is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1089318).
Chemical identity
- IUPAC name
- 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxidopyridin-1-ium-3-yl)-1,2,4-oxadiazol-5-yl]-3-nitrobenzene-1,2-diol
- Canonical SMILES
- CC1=C(C(=[N+](C(=C1Cl)C)[O-])Cl)C2=NOC(=N2)C3=CC(=C(C(=C3)O)O)[N+](=O)[O-]
- InChIKey
- ASOADIZOVZTJSR-UHFFFAOYSA-N
- Synonyms
- BIA 9-1067, BIA-9-1067, BIA-91067, Ongentys, Ontilyv, Opicapona, Opicapone, opicaponum, RefChem:57625, N04BX04, Opicapone?, Opicapone [INN]
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Catechol-O-Methyltransferase Inhibitor
- Mechanism of action
- Catechol O-Methyltransferase Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Opicapone?
4 organisations hold an active US FDA Type II Drug Master File or a CEP for Opicapone: BIAL PORTELA AND CA SA, Hetero Labs Limited (India), Jiangxi Synergy Pharmaceutical Co., Ltd (China) and MSN LIFE SCIENCES PRIVATE LIMITED (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Opicapone Drug Master Files are active?
BIAL PORTELA AND CA SA (DMF 34838, 32198), Hetero Labs Limited (DMF 41566), Jiangxi Synergy Pharmaceutical Co., Ltd (DMF 42988) and MSN LIFE SCIENCES PRIVATE LIMITED (DMF 38110). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Opicapone?
Yes. The latest patent listed for an approved US product containing Opicapone expires 12 Dec 2032, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Opicapone supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Opicapone?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.